Support for research projects
Menu COVID-19
ANRS | Emerging Infectious Diseases, coordinating and accelerating French research on COVID-19
At a time when the Sars-CoV-2 epidemic is continuing to spread, France is mobilizing to accelerate research into the virus and COVID-19 disease through ANRS | Emerging Infectious Diseases, an autonomous agency of Inserm.
With the support of the Ministry of Solidarity and Health and the Ministry of Higher Education, Research and Innovation, and thanks to support from different funders, scientific initiatives selected by the ANRS | EID COVID-19 Scientific Advisory Board, could benefit from support from the consortium for a rapide implementation during the crisis.
Since the emergence of the first cases at the end of 2019, implementing high quality research to contain Sars-CoV-2 as quickly as possible and improve the treatment of those infected have been the objectives of the French scientific community, under the egis of the ANRS | Emerging Infectious Diseases network.
In the first weeks of the crisis, in February 2020, and following a call for applications made to research teams across France, the ANRS | EID COVID-19 Scientific Advisory Board selected 20 projects from a variety of scientific disciplines.
Chosen for their effective and exhaustive contributions to knowledge production and to fighting this new epidemic, these projects have been categorized as follows:
- Diagnostic, clinical and therapeutic research projects
- Epidemiology research projects
- Fundamental research projects
- Human and social science research projects
Key figures
Budget distribution according to categories
Other research projects with the support of REACTing-ANRS | EID
REACTing-ANRS | EID, in addition to providing financial support to some of the projects that have been elected for seed money, has been providing methodological or logistical support to numerous trials. The agency’s support has been key in setting up these projects from the very beginning of the crisis.
The CORIMUNO Projet is a cohort of multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19.
